MARKET

DIOD

DIOD

Diodes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

65.53
-0.69
-1.04%
Opening 12:38 11/25 EST
OPEN
66.00
PREV CLOSE
66.22
HIGH
66.46
LOW
65.11
VOLUME
111.83K
TURNOVER
--
52 WEEK HIGH
67.08
52 WEEK LOW
31.51
MARKET CAP
3.41B
P/E (TTM)
29.77
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Gilead Sciences to Present at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020
Business Wire · 1d ago
Remdesivirs Failure Is a Warning for Covid-19 Vaccines
(Bloomberg Opinion) -- Less than a month ago, the Food and Drug Administration said hospitals could use remdesivir, a drug manufactured by Gilead Sciences Inc., to treat patients with Covid-19. Remdesivir, sold under the brand name Veklury, was said to shorten recovery times and reduce the need for ventilators to facilitate breathing. Yesterday, the World Health Organization hit the brakes: It recommended that doctors avoid using the drug altogether.“There is currently no evidence that remdesivir improves survival and other outcomes in these patients,” the WHO noted, citing detailed studies it sponsored. “The evidence suggested no important effect on mortality, need for mechanical ventilation, time to clinical improvement, and other patient-important outcomes.”A group of experts gathered by the WHO concurred, reporting their findings in a well-regarded medical journal. Remdesivir offers “small and uncertain benefits” outweighed by the “possibility of important harms,” they wrote. Gilead pushed back, saying it stands by remdesivir and citing other studies supporting its efficacy.Speed is prized in the race to beat back Covid-19 — as it should be. The world is also fortunate to have innovative and dedicated public and private researchers able to produce coronavirus vaccine candidates in record time. But the WHO’s thumbs-down on remdesivir is also a reminder that hasty drug development and approval is risky. It highlights why the FDA has to do more than merely rubber-stamp Covid-19 treatments in the face of heavy White House pressure to move quickly.As my colleague Max Nisen recently observed, it’s perplexing that the FDA gave formal approval to remdesivir as a Covid-19 treatment in October. The drug was already available to hospitals and patients under a federal emergency use authorization granted in May. Since then, data supporting its benefits had become murky, and an FDA sign-off was unlikely to significantly expand its use. As I noted in an earlier column, remdesivir is also expensive — perhaps not as costly as other blockbuster drugs the pharmaceutical industry sells, but still expensive.Two writers for Science magazine, Jon Cohen and Kai Kupferschmidt, offered some answers to these mysteries in a deeply reported piece published late last month. They found that the FDA and the European Union both had approved the use of remdesivir despite some glaring procedural gaps. The FDA didn’t consult the outside experts it keeps on tap to analyze approvals for complex antiviral drugs. The EU approved remdesivir’s pricing just a week before lackluster results from a major WHO trial of the drug were published — and then seemed clueless about the new data. (Gilead was aware; it had donated drug to the trial and knew the results were poor.)The Science writers pointed out that the FDA’s inaction around remdesivir “stands in sharp contrast to its handling of potential Covid-19 vaccines.” For remdesivir, the agency failed to convene an advisory to study the drug. Several prominent medical researchers voiced skepticism about remdesivir in the Science article, including Martin Landry of Oxford University, who said the drug was useless for treating the sickest patients. In any case, most people with Covid-19 recover without medical treatment.“The argument that the earlier you use it the better is great until you realize what the implications of that are: You won’t save many lives, and you’ll have to treat a lot of patients,” Landry told Science. “It’s very inconvenient, and it’ll cost you a fortune.”Perhaps it was inevitable that Gilead would receive special treatment. In May, when remdesivir was given its EUA, the company’s chief executive officer, Daniel O’Day, was welcomed into the Oval Office for a photo op with President Donald Trump and FDA Commissioner Stephen Hahn. Trump, who was treated with remdesivir after contracting Covid-19 himself, has described it as one of a handful of drugs he received that were like “miracles coming down from God.”Hospitals have been less enthusiastic and have been sharply cutting back their use of remdesivir due to its expense and its value for only the most seriously ill patients — which makes the FDA’s enthusiasm for the drug and its manufacturer all the more curious. The FDA approved remdesivir based on three trials, the most weighty of which was conducted by the National Institutes of Health. Both the NIH and the FDA are housed under the Department of Health and Human Services.Perhaps it was just fine that the FDA relied on what was essentially an in-house trial to approve remdesivir and that Hahn has been unusually amenable to Trump’s demands for approving sketchy Covid-19 treatments. And perhaps it’s fine that Alex Azar, a former pharmaceutical executive and Big Pharma lobbyist who is a Trump loyalist, runs HHS and supervises Hahn.In case any of this isn’t fine, we should bear it in mind as HHS and the FDA continue to play pivotal roles overseeing the approval, rollout and regulation of more crucial drugs: the Covid-19 vaccines that Pfizer Inc. and Moderna Inc. have put on the table.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Timothy L. O'Brien is a senior columnist for Bloomberg Opinion.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Bloomberg · 4d ago
Coronavirus update: U.S. moves closer to 200,000 cases a day; Birx and Fauci urge Americans to follow safety measures over Thanksgiving
The global case tally for the coronavirus illness COVID-19 climbed above 57 million on Friday, and the U.S. moved closer to 200,000 cases in a day and set a...
MarketWatch · 5d ago
Nasdaq-100 Laggards Could Offer Timely Short Sales
The Nasdaq-100's weakest stocks could generate short sale profits during tax-selling season.
Investopedia · 5d ago
California to Begin Overnight Lockdown
Here’s what you need to know about the impact of Covid-19 to navigate the markets today.
Barrons.com · 5d ago
Lilly's arthritis drug and Gilead's Veklury receive FDA authorization as combination COVID-19 treatment
Shares of Eli Lilly & Co. undefined gained 0.6% in premarket trading on Friday, the day after the Food and Drug Administration granted an emergency use...
MarketWatch · 5d ago
Coronavirus update: Pfizer/BioNTech press for emergency vaccine use as WHO hits Gilead's remdesivir
Vaccine optimism rises with Pfizer/BioNTech emergency use authorization filing, as World Health Organization puts a cork in remdesivir.
Yahoo Finance · 5d ago
WHO advisers recommend against Gileads remdesivir for treating COVID-19
Shares of Gilead Sciences Inc. fell in after-hours trading Thursday after a World Health Organization panel recommended against doctors using the drug...
MarketWatch · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DIOD. Analyze the recent business situations of Diodes through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DIOD stock price target is 72.17 with a high estimate of 84.00 and a low estimate of 63.00.
EPS
Institutional Holdings
Institutions: 360
Institutional Holdings: 44.87M
% Owned: 86.22%
Shares Outstanding: 52.04M
TypeInstitutionsShares
Increased
70
1.06M
New
44
890.91K
Decreased
93
1.50M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Semiconductors
+0.14%
Semiconductors & Semiconductor Equipment
-0.05%
Key Executives
Chairman/President/Chief Executive Officer/Director
Keh-Shew Lu
Chairman/President/Chief Executive Officer/Director
Keh Shew Lu
Vice Chairman/Independent Director
Chung Chen
Vice Chairman/Independent Director
C. H. Chen
Chief Financial Officer
Brett Whitmire
Vice President - Operations
Julie Holland
Vice President/Director of Sales/Director of Marketing
Emily Yang
Vice President
Francis Tang
Vice President
Evan Yu
Secretary
Richard White
Lead Director/Independent Director
Michael Tsai
Independent Director
Warren Chen
Independent Director
Michael Giordano
Independent Director
Peter Menard
Independent Director
Christina Sung
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DIOD
Diodes Incorporated is a manufacturer and supplier of application-specific standard products within the discrete, logic, analog and mixed-signal semiconductor markets, serving the consumer electronics, computing, communications, industrial and automotive markets. The Company's products include diodes; rectifiers; transistors; metal-oxide semiconductor field-effect transistors (MOSFETs); protection devices; amplifiers and comparators; Hall-effect and temperature sensors, and power management devices, including light emitting diode (LED) drivers, alternating current (AC)-direct current (DC) and DC-DC switching, linear voltage regulators and voltage references, along with special function devices, such as universal serial bus (USB) power switches, load switches, voltage supervisors and motor controllers. It also holds interests in Pericom Semiconductor Corporation, which designs, develops and markets integrated circuits (ICs) and frequency control products (FCPs).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Diodes Incorporated stock information, including NASDAQ:DIOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DIOD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DIOD stock methods without spending real money on the virtual paper trading platform.